Last reviewed 2026-04-20 · How we verify

Paroxon (PAROXYPROPIONE)

Phase 2 active Small molecule

Paroxon (generic name: PAROXYPROPIONE) is a paroxypropione drug. It is currently in Phase 2 development.

Paroxon is thought to work by interacting with a specific molecular target, although the exact nature of this interaction is not yet understood.

Paroxon, also known as paroxypropione, is a small molecule drug of the paroxypropione class. Its exact target and mechanism of action are unknown, and it has not been approved by the FDA for any indications. The commercial status of Paroxon is unclear, with no information available on its patent status, generic manufacturers, or off-patent status. Further research is needed to determine the safety and efficacy of Paroxon. As a result, it is not currently available for clinical use.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	PAROXYPROPIONE
Drug class	paroxypropione
Modality	Small molecule
Therapeutic area	Other
Phase	Phase 2

Mechanism of action

Imagine your body's cells are like locks, and Paroxon is a key that fits into one of those locks. When it binds to the lock, it can either turn it on or off, depending on the type of lock and the key. This can help to regulate various bodily functions, but more research is needed to understand exactly how Paroxon works and what effects it has on the body.

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Paroxon CI brief — competitive landscape report
Paroxon updates RSS · CI watch RSS

Frequently asked questions about Paroxon

What is Paroxon?

Paroxon (PAROXYPROPIONE) is a paroxypropione drug.

How does Paroxon work?

Paroxon is thought to work by interacting with a specific molecular target, although the exact nature of this interaction is not yet understood.

What is the generic name of Paroxon?

PAROXYPROPIONE is the generic (nonproprietary) name of Paroxon.

What drug class is Paroxon in?

Paroxon belongs to the paroxypropione class. See all paroxypropione drugs at /class/paroxypropione.

What development phase is Paroxon in?

Paroxon is in Phase 2.

Drug class: All paroxypropione drugs
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing